Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046
Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203) has successfully completed the enrollment of all patients in China, and the interim analysis is expected in the...
Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference
INCHEON, South Korea, Jan. 13, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually from January 10th to 13th with leaders from major pharmaceutical and biopharmaceutical companies and key investors. During the main track presentation today, John Rim, President and CEO...
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) The National Medical Products Administration (NMPA) of China has granted the Breakthrough Therapy Designation (BTD) to sugemalimab for the treatment of adult patients with R/R ENKTL GEMSTONE-201 is the first successful...
Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference
SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr. Jong-Yoon Chun, CEO of Seegene, proposed three strategic solutions that induce the...
Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 13, 2022 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion and...
Largest Global Health Network Havas Health & You Certified As “Great Place to Work”
NEW YORK, Jan. 12, 2022 /PRNewswire/ -- On the heels of a year that continued to cement health as more important than ever, the largest global health network Havas Health & You today announced that it has been named a "Great Place to Work", with employees reporting more than 20% higher satisfaction...
Dr. Michael Lilly elected to Chair of Inteleos Board of Directors
ROCKVILLE, Md., Jan. 12, 2022 /PRNewswire/ -- Inteleos™, a non-profit healthcare certification organization, today announced Dr. Michael Lilly, MD, RVT, RPVI, has been named as Chairperson of its Board of Directors. A long-time volunteer with Inteleos and its ARDMS Council, Dr. Lilly brings extensive experience in the field of vascular surgery and vascular ultrasound to this role. His term...
Evolved by Nature Announces IDE Approval from the FDA to Initiate a Pivotal Clinical Trial for its first Activated Silk™ Dermal Filler
BOSTON, Jan. 12, 2022 /PRNewswire/ -- Biotechnology company Evolved by Nature announced today that sister company Silk Medical Aesthetics has received Investigational Device Exemption (IDE) approval from the FDA to initiate a pivotal clinical trial for its new dermal filler for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. The new filler leverages Evolved...
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient had been dosed in its China phase 2 study (NCT05145907) of efineptakin alfa (also known as TJ107) in combination...
Gracell Biotechnologies Unveils Innovation Center in U.S.
SUZHOU, China and PALO ALTO, Calif., Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its newly established research facility, the Innovation Center, is...
